Af­ter lengthy con­sid­er­a­tion, a DC fed­er­al judge on Mon­day re­ject­ed Mer­ck’s chal­lenge to Medicare drug price ne­go­ti­a­tions.

Judge Colleen Kol­lar-Kotel­ly of the US Dis­trict Court...

The FDA is push­ing back its de­ci­sion on Capri­cor Ther­a­peu­tics’ prob­lem­at­ic Duchenne mus­cu­lar dy­s­tro­phy ther­a­py to re­view ad­di­tion­al da­ta for a more niche in­di­ca­tion.

The...

Roche is spend­ing $190 mil­lion up­front to li­cense a non-in­cretin obe­si­ty drug from South Ko­rea’s Han­mi Pharm.

The deal rep­re­sents the lat­est in a string...

Two re­cent deals are fo­cus­ing at­ten­tion on a rel­a­tive­ly rare struc­ture for biotech buy­outs: the op­tion-to-ac­quire.

Drug de­vel­op­ers are on pace to have one of...

Twin­Strand Bio­sciences wins patent case: The DNA se­quenc­ing com­pa­ny, which spun out of the Uni­ver­si­ty of Wash­ing­ton, an­nouncedon Mon­day that it won a patent...

Re­genxbio said it no longer ex­pects to file for FDA ap­proval of its Hunter syn­drome gene ther­a­py in the near fu­ture af­ter the pro­gram was...